RhoGDI2 has been shown to be upregulated in hepatocellular carcinoma (HCC) cells where its overexpression increased their rates of proliferation and invasion, via activating the PI3K/Akt pathway and increasing the levels of MMP2 and MMP9 (consistent to PDAC). This evidence concerns the gene ARHGDIB and hepatocellular carcinoma.